2456. Immunogenicity and Safety of a MenACWY-CRM Booster Dose 4–6 Years After Primary Quadrivalent Meningococcal Conjugate Vaccination in Healthy US Adolescents and Adults
Abstract:Background
Neisseria meningitidis serogroups A, B, C, W, and Y are a leading cause of bacterial meningitis and sepsis worldwide. Infants <1 year, adolescents and young adults are at the highest risk. The US Advisory Committee on Immunization Practices (ACIP) recommends routine MenACWY conjugate vaccination for adolescents at 11–12 years of age, with a booster dose 5 years later. We examined responses to a booster dose of MenACWY-CRM given 4–6 years after primary vaccination with a licensed quadrivalent meningo… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.